The aHUS therapy landscape is on the cusp of disruption-with emerging oral drugs and biosimilars reshaping market dynamics ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved a new Opdivo (nivolumab) ...

The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) ...

Bristol Myers Squibb has won European approval of a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin. Bristol Myers on Wednesday said the European Commission ...

for a new subcutaneous (SC) formulation of Opdivo (nivolumab), marking a significant advancement in the administration of cancer treatments. According to InvestingPro analysis, BMY maintains a ...

The subcutaneous formulation of nivolumab, co-formulated with rHuPH20, is approved for multiple solid tumor indications in the EU and Canada. The CheckMate-67T trial showed subcutaneous nivolumab's ...

With an increasing number of subcutaneous drugs available in cancer treatment, oncology nurses are spending more time administering these injections, which can lead to exhaustion and soreness.